Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Results From the ROADMAP Study by Estep, Jerry D. et al.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 6 , N O . 1 6 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 5 . 0 7 . 0 7 5ORIGINAL INVESTIGATIONSRisk Assessment and Comparative
Effectiveness of Left Ventricular
Assist Device and Medical Management
in Ambulatory Heart Failure Patients
Results From the ROADMAP StudyJerry D. Estep, MD,* Randall C. Starling, MD, MPH,y Douglas A. Horstmanshof, MD,z Carmelo A. Milano, MD,x
Craig H. Selzman, MD,k Keyur B. Shah, MD,{ Matthias Loebe, MD, PHD,* Nader Moazami, MD,y
James W. Long, MD, PHD,z Josef Stehlik, MD, MPH,k Vigneshwar Kasirajan, MD,{ Donald C. Haas, MD,#
John B. O’Connell, MD,** Andrew J. Boyle, MD,yy David J. Farrar, PHD,** Joseph G. Rogers, MD,x
for the ROADMAP Study InvestigatorsJACC JOURNAL CMEThis article has been selected as the month’s JACC Journal CME activity,
available online at http://www.acc.org/jacc-journals-cme by selecting the
CME tab on the top navigation bar.
Accreditation and Designation Statement
The American College of Cardiology Foundation (ACCF) is accredited by
the Accreditation Council for Continuing Medical Education (ACCME) to
provide continuing medical education for physicians.
The ACCF designates this Journal-based CME activity for a maximum
of 1 AMA PRA Category 1 Credit(s). Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Method of Participation and Receipt of CME Certiﬁcate
To obtain credit for JACC CME, you must:
1. Be an ACC member or JACC subscriber.
2. Carefully read the CME-designated article available online and in this
issue of the journal.
3. Answer the post-test questions. At least 2 out of the 3 questions
provided must be answered correctly to obtain CME credit.
4. Complete a brief evaluation.
5. Claim your CME credit and receive your certiﬁcate electronically by
following the instructions given at the conclusion of the activity.
CME Objective for This Article: At the end of this activity the reader
should be able to: 1) identify characteristics of ambulatory heart failure
patients who may beneﬁt from LVAD therapy; 2) evaluate treatment
options for patients with advanced ambulatory heart failure to improveFrom the *Houston Methodist Hospital, Houston, Texas; yCleveland Clinic,
Oklahoma City, Oklahoma; xDuke University, Durham, North Carolina; kUnive
wealth University, Richmond, Virginia; #AbingtonMemorial Hospital, Abingto
California;andtheyyPiedmontHospital,Atlanta,Georgia.TheROADMAPtrialwquality of life; 3) discuss with ambulatory heart failure patients the
projected beneﬁts and adverse events associated with the use of LVAD
therapy or continued optimal medical management; 4) respond to pa-
tient concerns about LVAD therapy and provide clinical data to guide
therapy decisions; and 5) recognize the difference in the reasons why
patients agree to and/or choose LVAD therapy in comparison to
continuing with optimal medical management.
CME Editor Disclosure: JACC CME Editor Ragavendra R. Baliga, MD, has
reported that he has no relationships to disclose.
Author Disclosures: The ROADMAP trial was sponsored and conducted by
Thoratec Corporation. Drs. Estep, Starling, Horstmanshof, Shah, Loebe,
Moazami, Long,Milano, Stehlik, Kasirajan,Haas, andRogers have received
grant/research support from Thoratec. Drs. Estep, Horstmanshof, and
Boyle have served as consultants for Thoratec. Dr. Estep has served as a
consultant for Maquet. Dr. Starling has served as amember of the steering
committee for Thoratec. Dr. Haas served on the Thoratec speakers bureau.
Dr. Kasirajan served as a consultant for Syncardia. Drs. O’Connell and
Farrar are Thoratec employees. Dr. Farrar is a Thoratec stockholder.
Dr. Selzman has reported that he has no relationships relevant to the
contents of this paper to disclose.
Medium of Participation: Print (article only); online (article and quiz).
CME Term of Approval
Issue Date: October 20, 2015
Expiration Date: October 19, 2016Cleveland, Ohio; zINTEGRIS Baptist Medical Center,
rsity of Utah, Salt Lake City, Utah; {Virginia Common-
n, Pennsylvania; **Thoratec Corporation, Pleasanton,
as sponsoredandconductedbyThoratecCorporation.
Estep et al. J A C C V O L . 6 6 , N O . 1 6 , 2 0 1 5
Effectiveness of LVAD in Ambulatory HF O C T O B E R 2 0 , 2 0 1 5 : 1 7 4 7 – 6 1
1748Risk Assessment and Comparative Effectiveness of
Left Ventricular Assist Device and Medical
Management in Ambulatory Heart Failure Patients
Results From the ROADMAP StudyABSTRACTDr
gra
ser
the
plo
pa
Lis
MaBACKGROUND Data for left ventricular assist devices (LVADs) in patients with noninotrope-dependent heart failure
(HF) are limited.
OBJECTIVES The goal of this study was to evaluate HeartMate II (HMII) LVAD support versus optimal medical man-
agement (OMM) in ambulatory New York Heart Association functional class IIIB/IV patients meeting indications for LVAD
destination therapy but not dependent on intravenous inotropic support.
METHODS This was a prospective, multicenter (N¼ 41), observational study of 200 patients (97 LVAD, 103 OMM). Entry
criteria included $1 hospitalization for HF in the last 12 months and 6-min walk distance (6MWD) <300 m. The primary
composite endpoint was survival on original therapy with improvement in 6MWD $75 m at 12 months.
RESULTS LVAD patients were more severely ill, with more patients classiﬁed as Interagency Registry for Mechanically
Assisted Circulatory Support proﬁle 4 (65% LVAD vs. 34% OMM; p < 0.001) than 5 to 7. More LVAD patients met the
primary endpoint (39% LVAD vs. 21% OMM; odds ratio: 2.4 [95% conﬁdence interval: 1.2 to 4.8]; p ¼ 0.012). On the
basis of as-treated analysis, 12-month survival was greater for LVAD versus OMM (80  4% vs. 63  5%; p ¼ 0.022)
patients. Adverse events were higher in LVAD patients, at 1.89 events/patient-year (EPPY), primarily driven by bleeding
(1.22 EPPY), than with OMM, at 0.83 EPPY, primarily driven by worsening HF (0.68 EPPY). Most patients (80% LVAD vs.
62% OMM; p < 0.001) required hospitalizations. Health-related quality of life (HRQol) and depression improved from
baseline more signiﬁcantly with LVADs than with OMM (D visual analog scale: 29  25 vs. 10  22 [p < 0.001]; D Patient
Health Questionnaire–9: –5  7 vs. –1  5 [p < 0.001]).
CONCLUSIONS Survival with improved functional status was better with HMII LVAD compared with OMM. Despite
experiencing more frequent adverse events, LVAD patients improved more in HRQol and depression. The results support
HMII use in functionally limited, noninotrope-dependent HF patients with poor HRQoL. (Risk Assessment and Compar-
ative Effectiveness of Left Ventricular Assist Device [LVAD] and Medical Management [ROADMAP]; NCT01452802)
(J Am Coll Cardiol 2015;66:1747–61) © 2015 by the American College of Cardiology Foundation.T herapy with a left ventricular assist device(LVAD) is an established treatment forpatients with advanced heart failure (HF).
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ABBR EV I A T I ON S
AND ACRONYMS
6MWD = 6-min walk distance
DT = destination therapy
EPPY = events per patient-year
EQ-5D = EuroQol
HF = heart failure
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1749outweigh the risks (4). Consequently, the majority of
LVAD implantations are performed in patients who
are hospitalized and dependent on intravenous
inotropic support. At present, there are no data from
clinical trials or registries to inform physicians or pa-
tients about the relative risks and beneﬁts of LVAD
therapy or optimal medical management (OMM) in
noninotrope-dependent HF.SEE PAGE 1762
HMII = HeartMate II
HRQoL = health related quality
of life
INTERMACS = Interagency
Registry for Mechanically
Assisted Circulatory Support
LVAD = left ventricular assist
device
NYHA = New York Heart
Association
OMM = optimal medical
management
PHQ-9 = Patient Health
Questionnaire–9
= visual analog scaleThe INTERMACS (Interagency Registry for Me-
chanically Assisted Circulatory Support) has compiled
data from >10,000 LVAD-supported patients since
June 2006 (5). Actuarial survival for all patients with
continuous-ﬂow LVADs at 1 and 2 years has reached
80% and 70%, respectively, with 1-year survival of
75% for DT. Eighty percent of patients in INTERMACS
were treated with pre-implantation inotropes (pro-
ﬁles 1 to 3), with fewer data on patients with less
advanced disease (proﬁles 4 to 7). The risk/beneﬁt
tradeoff of LVADs versus OMM in this patient cohort
is not well understood. Boyle et al. (6) reported a 95%
twelve-month survival, shorter implantation hospi-
talization, and lower costs in LVAD patients with
advanced HF who were classiﬁed INTERMACS pro-
ﬁles 4 to 7 at LVAD implantation. Jorde et al. (7)
recently published results of the HeartMate II (HMII)
DT Post Approval study and reported 1-year survival
of 82% for patients not yet treated with inotropes
(INTERMACS proﬁles 4 to 7) compared with 71% sur-
vival for those with proﬁles 1 to 3. Furthermore,
Grady et al. (8) showed that health-related quality of
life (HRQoL) is signiﬁcantly improved with LVAD
support in all INTERMACS proﬁles, including 4 to 7.
Relatively high adverse event (AE) rates associ-
ated with LVADs (5) may limit adoption of the
therapy. Furthermore, there are limited prospective
data comparing the relative risks (AEs) and beneﬁts
(functional capacity and quality of life improvement)
of LVAD treatment versus OMM. The goal of the
present study was to report results from a large
observational clinical study of the HMII continuous-
ﬂow LVAD in advanced, ambulatory HF patients who
are not dependent on intravenous inotropic support
and who meet U.S. Food and Drug Administration–
approved indications for LVAD DT.
METHODS
STUDY DESIGN. ROADMAP is a prospective, non-
randomized, observational study comparing LVAD
support versus OMM. Details of the ROADMAP study
design, rationale, and power analysis for sample
size were previously reported (9). The study wasconducted at 41 U.S. centers and supervised
by the sponsor (Thoratec Corporation, Pleas-
anton, California). A complete list of all
participating centers is listed in the Online
Appendix. Enrollment was between October
2011 and July 2013, and patients are being
followed for up to 2 years. The primary
endpoint was at 1 year and is the focus of the
present analysis. The trial was collaboratively
designed by the sponsor and the clinical in-
vestigators. Coordinators at each site
collected all data, which were entered into an
electronic data capture system for analysis by
the sponsor. The academic authors had inde-
pendent access to the data and vouch for the
completeness and accuracy of the data and
the analyses. Trial enrollment and conduct
were monitored by a steering committee of
cardiologists, cardiac surgeons, and sponsor
representatives. A biostatistician indepen-
dent of the sponsor and the investigators
provided an independent validation of study
results. The institutional review board at each
participating center approved the protocol.
STUDY SUBJECTS. Inclusion and exclusion criteria
were previously reported (9). Patients with advanced
HF, deﬁned as New York Heart Association (NYHA)
functional class IIIB/IV symptoms, who were not
dependent on intravenous inotropic support and met
the U.S. Food and Drug Administration–approved in-
dications for HMII LVAD DT, including an ejection
fraction #25% and treatment with guideline-based
OMM for 45 of the past 60 days (or intolerant to these
medications), were eligible for study enrollment.
Implantable deﬁbrillators and cardiac resynchroniza-
tion therapy were recommended according to con-
temporary guidelines, and this resynchronization
therapy had to be implanted at least 3 months before
enrollment. To capture a higher risk population, pa-
tients had to have 1 HF hospitalization or 2 unsched-
uled emergency department/infusion clinic visits in
the previous year and functional exercise impairment
with a baseline 6-min walk distance (6MWD) <300 m.
The LVAD cohort comprised subjects who met
study entrance criteria and who elected to undergo
HMII LVAD implantation. The OMM cohort consisted
of subjects who met study entrance criteria, including
the DT indications for HMII, but elected to remain on
OMM (on the basis of patient and/or physician
choice). Participating patients provided written
informed consent before enrollment.
BASELINE ASSESSMENT. Baseline assessments in-
cluded demographic characteristics, health history,
VAS
TABLE 1 Baseline Characteristics for All Patients
OMM (n ¼ 103) LVAD (n ¼ 97) p Value
Enrollment age, yrs 66 (54–74) 64 (55–70) 0.269
Male 71 (69) 75 (77) 0.204
Race 0.061
White 60 (58) 72 (74)
Black 35 (34) 21 (22)
Other 8 (8) 4 (4)
Ischemic etiology 51 (50) 58 (60) 0.158
History of atrial ﬁbrillation 36 (35) 42 (43) 0.248
Duration of HF >1 yr 95 (92) 91 (94) 0.784
CRT or CRT-D 43 (42) 44 (45) 0.669
ICD or CRT-D 66 (64) 67 (69) 0.549
Diuretic dose furosemide-equivalent, mg/day 93 (40–200) 133 (40–240) 0.127
ACE inhibitors or ARBs 79 (77) 66 (68) 0.205
Beta-blockers 99 (96) 84 (87) 0.021
BMI, kg/m2 28 (23–37) 29 (25–33) 0.663
Creatinine, mg/dl 1.3 (1.0–1.8) (n ¼ 103) 1.3 (1.0–1.6) (n ¼ 97) 0.507
BUN, mg/dl 28 (21–40) (n ¼ 103) 26 (18–34) (n ¼ 97) 0.120
eGFR, ml/min/1.73 m2 63 (45–90) (n ¼ 103) 70 (53–100) (n ¼ 97) 0.123
AST, U/l 26 (20–36) (n ¼ 100) 28 (21–46) (n ¼ 97) 0.067
Albumin, g/dl 4.0 (3.6–4.3) (n ¼ 99) 3.7 (3.4–4.2) (n ¼ 94) 0.045
NT–pro-BNP, pg/ml 2,696 (1,369–6,369) (n ¼ 27) 3,815 (2,160–5,320) (n ¼ 26) 0.922
Serum BNP, pg/ml 737 (274–1,165) (n ¼ 62) 547 (308–829) (n ¼ 59) 0.391
Cardiac index, l/min/m2 1.9 (1.6–2.3) (n ¼ 50) 1.9 (1.6–2.3) (n ¼ 65) 0.921
PCWP, mm Hg 22 (17–30) (n ¼ 50) 22 (17–27) (n ¼ 61) 0.425
PVR, Wood units 3.3 (2.3 – 4.6) (n ¼ 38) 3.1 (1.7–5.1) (n ¼ 50) 0.797
6MWD, m 219 (157–269) (n ¼ 103) 182 (122–259) (n ¼ 97) 0.057
VO2 max, ml/kg/min 9.7 (8.5–12.3) (n ¼ 61) 10.2 (8.7–11.5) (n ¼ 72) 0.977
VO2 max RER $ 1.1, ml/kg/min 10.9 (9.6–12.7) (n ¼ 23) 10.2 (8.8–11.3) (n ¼ 27) 0.131
VE/VCO2 37.4 (34.0–49.0) (n ¼ 51) 44.0 (36.9–49.0) (n ¼ 58) 0.090
EQ-5D VAS 55 (45–75) (n ¼ 99) 50 (30–60) (n ¼ 93) <0.001
SHFM score 1.43 (0.89–2.03) (n ¼ 103) 1.79 (1.08–2.43) (n ¼ 97) 0.013
SHFM 1-yr predicted survival, % 84 (73–91) 78 (63–89) 0.012
HMRS 1.16 (0.57–1.94) (n ¼ 88) 1.40 (0.93–1.81) (n ¼ 93) 0.312
PHQ-9 score 7 (3–10) (n ¼ 101) 10 (6–15) (n ¼ 96) <0.001
PHQ-9 depression severity <0.001
None/minimal (0–4) 40 (40) 12 (13)
Mild (5–9) 32 (32) 32 (33)
Moderate (10–14) 16 (16) 27 (28)
Moderately severe (15–19) 9 (9) 21 (22)
Severe (20–27) 4 (4) 4 (4)
NYHA functional class <0.001
IIIB 77 (75) 47 (48)
IV 26 (25) 50 (52)
INTERMACS proﬁle <0.001
Proﬁle 4 35 (34) 63 (65)
Proﬁle 5 29 (28) 21 (22)
Proﬁle 6 35 (34) 10 (10)
Proﬁle 7 2 (2) 0
Values are median (quartile 1–3) or n (%).
6MWD ¼ 6-min walk distance; ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; AST ¼ aspartate aminotransferase; BMI ¼ body mass index;
BNP ¼ B-type natriuretic peptide; BUN ¼ blood urea nitrogen; CRT-D ¼ cardiac resynchronization therapy–deﬁbrillator; eGFR ¼ estimated glomerular ﬁltration rate;
EQ-5D ¼ EuroQol; HF ¼ heart failure; HMRS ¼ Heartmate II risk score; ICD ¼ implantable cardioverter-deﬁbrillator; INTERMACS ¼ Interagency Registry for Mechanically
Assisted Circulatory Support; LVAD ¼ left ventricular assist device; NYHA ¼ New York Heart Association; NT-proBNP ¼ N-terminal pro B-type natriuretic peptide; OMM ¼
optimal medical therapy; PCWP ¼ pulmonary capillary wedge pressure; PHQ-9 ¼ Patient Health Questionnaire–9; PVR ¼ pulmonary vascular resistance; RER ¼ respiratory
exchange ratio; SHFM ¼ Seattle Heart Failure Model; VAS ¼ visual analog score; VE/VCO2 ¼ ventilator-equivalent ratio for oxygen and carbon dioxide; VO2 max ¼ maximal
oxygen uptake.
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FIGURE 1 The ROADMAP Patients at 1 Year
All Patients
N = 200
OMM
N = 103
Died
N = 18
Original Therapy*
N = 58
Delayed LVAD
N = 18
Original Therapy†
N = 74
Heart Transplant‡
N = 3
Withdrawn
N = 9
Died
N = 17
Withdrawn
N = 3
LVAD
N = 97
Flow chart depicts outcomes and events within 12 months of enrollment in the ROADMAP (Risk Assessment and Comparative Effectiveness of
Left Ventricular Assist Device [LVAD] and Medical Management) trial. Patients who withdrew from the study or received an elective heart
transplant within 1 year were excluded from the primary endpoint analysis. *12 optimal medical management (OMM) patients missing 6-min
walk distance data were excluded from the primary endpoint analysis. †8 left ventricular assist device (LVAD) patients missing 6MWD data were
excluded from the primary endpoint analysis. ‡Includes 1 elective and 2 urgent transplants.
TABLE 2 Patient Questionnaire on QoL Satisfaction and Perception of Longevity on
Medical Management at Baseline
OMM LVAD p Value
At baseline, is the patient satisﬁed with current QoL on medical therapy?
n 101 95
Not or slightly satisﬁed 48 (48) 75 (79) <0.001
Moderately to extremely satisﬁed 53 (52) 20 (21)
I believe my current treatment (on medical therapy at baseline) will allow me to live:
n 100 90
<1 yr 9 (9) 48 (53) <0.001
>1 yr 91 (91) 42 (47)
I believe my QoL on current treatment (at baseline) will:
n 101 94
Decline 28 (28) 71 (76) <0.001
Remain the same 24 (24) 6 (6)
Improve 49 (49) 17 (18)
Was the patient previously aware of LVAD therapy?
n 100 93
Yes 56 (56) 43 (46) 0.196
No 44 (44) 50 (54)
Values are n (%) of patients responding to question.
QoL ¼ quality of life; other abbreviations as in Table 1.
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1751NYHA functional class, and INTERMACS proﬁles as
determined at the site by an independent assessor (an
advanced practice practitioner other than the prin-
cipal investigator), blood chemistry, hematological
data, and concomitant medications. Two surveys were
also used, 1 on HRQoL (i.e., the EuroQol [EQ-5D-5L]
[10], including the visual analog scale [VAS]) and
a depression-screening questionnaire, the Patient
Health Questionnaire–9 (PHQ-9) (11). Additional base-
line functional status was assessed by using the
6MWD.
Cardiopulmonary exercise testing (maximal oxy-
gen consumption) data were captured when avail-
able. Factors related to patient and physician
decisions to proceed with LVAD therapy or continue
on OMM, as well as patients’ perceptions of survival
on current therapy, were captured by using baseline
questionnaires.
FOLLOW-UP AFTER DEVICE IMPLANTATION OR
CONTINUED MEDICAL THERAPY. After LVAD implan-
tation, an antithrombotic regimen (typically heparin,
followed by warfarin and aspirin) was implemented
and managed according to each center’s standard of
care. Follow-up assessments were made every 3 or
6 months for up to 24 months (9). Clinical follow-up
included assessment of HRQol, depression, func-
tional status, and laboratory parameters. The preva-
lence, incidence, and cause of rehospitalizations were
documented. AEs were captured by using standard-
ized INTERMACS deﬁnitions.STATISTICAL ANALYSIS. The primary endpoint was
a composite of survival and improvement $75 m in
6MWD at 12 months. This outcome was evaluated on
all patients without adjustments for baseline severity
of illness. Differences between groups were analyzed
by using the Fisher exact test. LVAD patients who
received an urgent transplant after LVAD complica-
tions were counted as failures. OMM patients who
TABLE 3 Patient and Physician Reasons Provided for LVAD or OMM
Patient reasons*: LVAD, n ¼ 95
It will improve chances to live longer 81 (85)
It will improve QoL 79 (83)
It will help improve HF symptoms 72 (76)
It will help me return to activities I enjoy 72 (76)
Patient reasons: OMM, n ¼ 101
Don’t like the idea of major device implantation surgery 40 (40)
Don’t want to depend on a machine 26 (26)
Don’t feel sick enough 25 (25)
Worried about too many complications with a LVAD 21 (21)
Don’t think an LVAD will improve QoL 13 (13)
Don’t think an LVAD will improve chances to live longer 10 (10)
Physician reasons: OMM, n ¼ 103
Patient is not a good surgical candidate† 14 (14)
Patient is not sick enough 11 (11)
Other (e.g., substance abuse, ﬁnancial, compliance concerns) 9 (9)
Values are n (%) of patients who completed questionnaire. *Patients may select >1 response.
†Surgical reasons provided: history of anticardiolipin antibody and splenectomy (high risk of
clotting); lack of social support and noncompliance; medical nonadherence; interstitial ﬁbrosis;
obesity; liver cirrhosis; severe chronic obstructive pulmonary disease; concern regarding post-
operative recovery; large sacral decubitus ulcer; recent stroke.
Abbreviations as in Tables 1 and 2.
TABLE 4 Primary En
Alive at 12 months on
therapy with in
in 6MWD by 75
First event that prev
Death within 1 yr
Delayed LVAD
Delta 6MWD <75
Urgent transplant
Values are n (%). Odds ra
patients: 9 withdrawn, 12
heart transplant. ‡Includin
NA ¼ not applicable; oth
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1752crossed over to mechanical circulatory support,
including a total artiﬁcial heart, were counted as
delayed LVADs and as failures. Patients who with-
drew from the study before 12 months were not
included as either successes or failures in the primary
endpoint analysis. Actuarial survival as-treated was
determined with the Kaplan-Meier method through
12 months of support for LVAD patients free of urgent
transplantation and OMM patients free of LVAD or
transplantation. Survival was also determined under
the intention-to-treat principle. Differences between
groups were determined with the log-rank test. A
2-sided p value <0.05 was considered signiﬁcant.dpoint and Components that Prevented Success
OMM
(n ¼ 82)*
LVAD
(n ¼ 85)†
Odds Ratio
(95% Conﬁdence
Interval)
original
crease
m
17 (21) 33 (39) 2.4 (1.2–4.8)
p ¼ 0.012
ented success: 65 (79) 52 (61)
18 (22) 17 (20)
18 (22)‡ NA
m 29 (35) 33 (39)
0 2 (2)
tio is calculated (95% conﬁdence interval) as LVAD versus OMM. *Excluded OMM
missing 6MWD. †Excluded LVAD patients: 3 withdrawn, 8 missing 6MWD, 1 elective
g 1 total artiﬁcial heart.
er abbreviations as in Table 1.Continuous variables are reported as mean  SD or
SE or as median and quartiles. Categorical data are
reported as percentages with 2-sided 95% conﬁdence
limits. Differences between groups of independent,
normally distributed, continuous variables were
evaluated by using the 2-sample Student t test. Vari-
ables that were not normally distributed were
compared between treatments by using the Wilcoxon
rank sum test. The prevalence of patients with AEs
within 12 months and the incidence rate in events per
patient-year (EPPY) using all data were determined
for both groups. As a measure of the total burden of
major AEs, a composite event rate was calculated as
the sum of EPPY for bleeding, driveline infection,
pump thrombus, stroke, arrhythmias, and worsening
HF. Risk ratio evaluation and comparison of AE rates
were performed by using Cochran-Mantel-Haenszel
statistics.
Paired changes in functional parameters, 6MWD,
PHQ-9, and EQ-5D VAS from baseline to 12 months
were compared between treatments in patients sur-
viving to 12 months on original therapy by using
mixed-effects modeling on ranks; a Tukey adjust-
ment was used for pairwise comparisons. Post-hoc
composite endpoints were determined by using the
percentage of patients alive on original therapy at
12 months with improvement in the following pa-
rameters: 1) NYHA functional class; and 2) VAS of
>20 points in subjects with impaired HRQoL at
baseline, as deﬁned by baseline VAS <68 (top quartile
of values) and depression score improvement of at
least 5 points in patients at baseline with at least mild
depression (PHQ-9 $5). Differences between groups
were analyzed by using the Fisher exact test.
RESULTS
A total of 200 patients were enrolled in the study for
LVAD DT support (n ¼ 97) or continuing on OMM
(n ¼ 103) (Table 1, Figure 1). Most subjects were men
with a median age of 65 years (range 21 to 82 years).
Many baseline parameters were characteristic of a
patient population with advanced HF and were
overall similar between the LVAD and OMM groups.
However, patients in the LVAD group compared
with the OMM group were more severely ill (NYHA
functional class IV: 52% vs. 25%; INTERMACS proﬁle
4: 65% vs. 34%), had lower baseline HRQol, had more
severe depression (87% vs. 60% [at least mild
depression]), and had lower predicted Seattle Heart
Failure Model 12-month survival rates.
Patient questionnaires at baseline demonstrated
that more LVAD patients reported that they were not
satisﬁed or only slightly satisﬁed with their quality of
FIGURE 2 Survival As-Treated
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At 1 year, survival as-treated was signiﬁcantly higher in LVAD versus OMM patients. Hazard
ratio (HR) was calculated for OMM versus LVAD. Abbreviations as in Figure 1.
FIGURE 3 Intention-to-Treat Survival
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Intention-to-treat survival was not signiﬁcantly different between OMM and LVAD pa-
tients. HR was calculated for OMM versus LVAD. *One patient received a total artiﬁcial
heart and was censored alive, then withdrawn from the study. Abbreviations as in
Figures 1 and 2.
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1753life on baseline medical therapy (79%) compared with
those who remained on OMM (48%) (Table 2).
Signiﬁcantly more LVAD patients at baseline also
reported a perception that they were going to
live <1 year (53% vs. 9%). The main patient reasons
given for choosing OMM instead of LVAD include not
wanting major device surgery, not wanting to depend
on a machine, and not feeling sick enough (Table 3).
For patients who agreed to LVAD therapy, the main
reasons given were anticipated improvement in sur-
vival and improvements in quality of life and HF
symptoms.
STUDY COURSE. A ﬂow chart of all patients and
outcomes over the ﬁrst year is shown in Figure 1. Of
the 103 OMM patients, 18 died, 18 received a delayed
LVAD at least 1 month after enrollment (including
1 patient receiving a total artiﬁcial heart), and 9 pa-
tients withdrew from the study before reaching an
outcome, leaving 58 patients alive on original OMM
therapy at 12 months. The median time from enroll-
ment to delayed LVAD was 138 days (quartiles 1 to 3:
72 to 203 days). For the 97 patients in the LVAD arm,
17 died, 3 received a heart transplant (2 urgent and
1 elective), and 3 withdrew from the study within
30 days of enrollment before receiving an LVAD,
leaving 74 patients on LVAD support at 12 months.
PRIMARY ENDPOINT. More patients who received
LVAD support achieved the primary composite end-
point than patients who received OMM (39% [33/85]
vs. 21% [17/82]; odds ratio: 2.4 [95% conﬁdence
interval: 1.2 to 4.8]; p ¼ 0.012) (Table 4). The main
reason why fewer OMM patients met the primary
endpoint compared with the LVAD group was the use
of delayed LVADs in OMM patients.
ACTUARIAL SURVIVAL. Thirty-day operative mor-
tality after LVAD implantation was 1%, the same as
the mortality rate in the OMM group within 30 days
after enrollment. The median hospitalization length
of stay after LVAD implantation was 17 days (quartiles
1 to 3: 13 to 22 days). The 12-month as-treated (event-
free) survival (freedom from death, urgent heart
transplantation, or delayed LVAD) was signiﬁcantly
greater for LVAD versus OMM (80  4% vs. 63  5%;
hazard ratio: 1.71 [95% conﬁdence interval: 1.07 to
2.73], p ¼ 0.024) (Figure 2). Using an intention-
to-treat analysis, Kaplan-Meier survival (freedom
from death) at 12 months was similar in both groups
(82  4% vs. 81  4%; p ¼ 0.931) (Figure 3).
FUNCTIONAL STATUS AND QUALITY OF LIFE. LVAD
patients experienced greater improvements in func-
tional status and quality of life. Compared with
0% before implantation, 77% of LVAD patients im-
proved with NYHA functional class I (25%) or II (52%)at 12 months (Figure 4). Compared with 0% with class
I or II symptoms at baseline, 29% of OMM patients
alive at 12 months had NYHA functional class II (no
class I) symptoms. For LVAD patients, 39 of 71 (55%)
improved at least 2 NYHA functional classes
compared with 2 of 52 (4%) OMM patients (p < 0.001).
FIGURE 4 Changes in NYHA Classiﬁcation
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For 1-year survivors on original therapy, signiﬁcantly more LVAD patients improved to New York Heart Association (NYHA) functional class I or II
compared with OMM patients. Patients with missing NYHA classiﬁcations were excluded (6 OMM, 3 LVAD). Abbreviations as in Figure 1.
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1754Similarly, the average 6MWD improved signiﬁcantly
in LVAD patients (187 m to 263 m; average increase of
75 m; p < 0.001) compared with no signiﬁcant change
in OMMpatients (214 to 249m; average change of 35m;
p ¼ 0.325) (Figure 5).
The EQ-5D VAS improved to a signiﬁcantly greater
degree in the LVAD versus OMM groups at 12 months,FIGURE 5 Changes in 6MWD
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(A) Paired 6-min walk distance (6MWD) measurements at baseline and
change in 6MWD from baseline to 12 months. Values are mean  SE. Pa
Abbreviations as in Figure 1.with an average improvement of 29 points for LVAD
compared with 10 points for OMM (p < 0.001)
(Figure 6). This outcome was due to LVAD patients
starting with worse baseline VAS scores, which
increased to levels similar to OMM at 12 months.
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12 months for 1-year survivors on original therapy. (B) Average
tients with missing 6MWD were excluded (12 OMM, 8 LVAD).
FIGURE 6 Changes in Health-Related Quality of Life From the EQ-5D VAS
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(A) Paired visual analog scale (VAS) at baseline and 12 months for 1-year survivors on original therapy. (B) Average change in VAS from baseline
to 12 months for 1-year survivors on original therapy. Patients with missing VAS were excluded (6 OMM, 8 LVAD). *p < 0.05, ***p < 0.001 for
paired changes within study arm. þþþp < 0.001 for OMM versus LVAD. EQ-5D ¼ EuroQol; other abbreviations as in Figure 1.
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1755compared with OMM patients (average: 7 [mild
depression]). Over 12 months, the average values for
OMM patients remained the same, compared with
LVAD patients who improved from moderate to mild
(Figure 7). The composite measures combining sur-
vival on original therapy with improvements in NYHA
functional class, HRQoL, and depression all showed
signiﬁcantly greater change for LVAD than OMM
(Table 5).
ADVERSE EVENTS. AEs were more frequent in LVAD
patients than in OMM patients (Table 6). Bleeding was
the primary driver of LVAD AEs; together, surgical
and nonsurgical bleeding accounted for 65% of LVAD
events. Worsening HF, which accounted for 82% of
OMM events, was the primary driver of OMM AEs.
Pump thrombus occurred in 6 LVAD patients,
4 requiring pump exchange, with only 1 early event
within 90 days of implantation. The median interna-
tional normalized ratio at 6 and 12 months after
LVAD implantation was 2.1 (quartiles 1 to 3: 1.8
to 2.5) and 2.1 (quartiles 1 to 3: 1.7 to 2.5), respec-
tively. At 12 months, 70% of patients were re-
ceiving warfarin and antiplatelet therapy (mostly
aspirin), 19% were receiving warfarin only, 8% were
receiving antiplatelet therapy only, and 3% were on
neither warfarin nor antiplatelet agents. The com-
posite AE rate for bleeding, driveline infection, pumpthrombosis, stroke, ventricular arrhythmias, and
worsening HF was 1.89 EPPY (LVAD) versus 0.83
EPPY (OMM), resulting in a relative risk for OMM
versus LVAD of 0.44 (95% conﬁdence interval: 0.35 to
0.56; p < 0.001). Gastrointestinal bleeding was the
main bleeding event, accounting for almost two-
thirds of all bleeding events, and one-half of the
events occurred in 4 patients. Without bleeding, the
composite AE rates were similar. More LVAD patients
(80%) than OMM patients (62%) had rehospitaliza-
tions within 1 year of enrollment, with the reasons
shown in Table 7. The leading causes of rehospitali-
zations were bleeding for LVAD patients and wors-
ening HF for OMM patients. OMM patients who
received delayed LVADs had deteriorated from base-
line, as evidenced by decreased serum albumin
levels, 6MWD, NYHA classiﬁcation, and INTERMACS
proﬁle (Table 8).
The leading causes of death among the 17 patients
who died with LVAD support were as follows: sepsis
(n ¼ 3 [17.6%]); multiorgan/renal failure (n ¼ 3
[17.6%]); right HF/ventricular tachycardia (n ¼ 2
[11.7%]); thrombus (n¼ 2 [11.7%]); and 1 (5.8%) each for
hemorrhagic stroke, ischemic stroke, bleeding/pleural
effusion, respiratory failure, car accident, pulmonary
embolism, and unknown. Among the 18 patients in
the OMM group, the leading causes of death were
FIGURE 7 Changes in Depression From PHQ-9
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(A) Paired Patient Health Questionnaire–9 (PHQ-9) scores at baseline and 12 months for 1-year survivors on original therapy. (B) Average
change in PHQ-9 score from baseline to 12 months for 1-year survivors on original therapy. Patients with missing PHQ-9 scores were excluded
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Abbreviations as in Figure 1.
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1756progressive HF (n ¼ 13 [72.2%]), with 1 (5.6%) each for
sudden cardiac death, chronic obstructive pulmonary
disease, sepsis, cancer, and unknown.
RISK/BENEFIT ANALYSIS. Figure 8 displays a sum-
mary of the beneﬁts and risks of LVAD therapy versus
OMM for patients in the ROADMAP study. LVAD pa-
tients were >2 times as likely to reach the primary
composite endpoint, and their survival as-treated on
original therapy was signiﬁcantly greater. LVAD pa-
tients also had a signiﬁcantly greater chance of being
alive at 12 months with improvements in NYHA
functional class, HRQoL, and depression. However,
OMM patients experienced less than one-half the AEs
as LVAD patients.TABLE 5 Secondary Composite Endpoints
Alive at 12 Months on Original Therapy With:
Improvement in NYHA functional class of at least 1 functional class
Improvement in NYHA functional class of at least 2 functional classes
Improvement in HRQoL VAS of more than 20 points in patients with
impaired baseline HRQoL*
Improvement in PHQ-9 of at least 5 points in patients with at least mild
or worse depression†
Values are n/N (%). Odds ratio is calculated (95% conﬁdence interval) LVAD versus OMN. *
baseline PHQ-9 $5 (mild or more severe), thus excluding those with no or minimal depr
HRQoL ¼ health-related quality of life; other abbreviations as in Table 1.DISCUSSION
The success of LVAD therapy, predominantly in pa-
tients with INTERMACS proﬁles 1 to 3, has been well
documented in clinical trials (2,3,5,12). The ROAD-
MAP study, as the ﬁrst prospective controlled study
in patients with advanced ambulatory, noninotrope-
dependent HF, found that LVAD therapy signiﬁ-
cantly improved survival, with improvement in
6MWD $75 m at 12 months relative to OMM. The
study’s observational nature resulted in an imbalance
in the severity of illness between the OMM and LVAD
patients, as many centers are more likely to delay use
of LVAD in the least ill patients. Comparisons of the
study arms are made with the acknowledgement thatOMM LVAD
Odds Ratio
(95% Conﬁdence Interval) p Value
17/88 (19) 62/91 (68) 8.9 (4.5–17.8) <0.001
2/88 (2) 39/91 (43) 32.3 (7.5–139.2) <0.001
13/56 (23) 41/74 (55) 4.1 (1.9–8.9) <0.001
8/51 (16) 33/75 (44) 4.2 (1.7–10.2) <0.001
Includes patients in bottom 3 quartiles of baseline VAS (<68). †Includes patients with
ession.
TABLE 6 Adverse Events
OMM (n ¼ 103) LVAD (n ¼ 94)
DT Trial§
(EPPY)
Bleeding 1 (1) [0.02] 44 (47) [1.22]‡ 1.13
GI bleeding 1 (1) [0.02] 29 (31) [0.76]‡k —
Driveline infection — 9 (9.6) [0.14]‡ 0.22
Pump thrombus — 6 (6.4) [0.08]† 0.07¶
Within 90 days — 1 (1.1) —
Pump exchange yr 1 — 4 (4.3) 2.1%
Stroke 2 (2) [0.02] 8 (8.5) [0.09]* 0.08
Ischemic 1 (1) [0.01] 5 (5.3) [0.06]* 0.05
Hemorrhagic 1 (1) [0.01] 4 (4.3) [0.03] NS 0.03
Arrhythmias VT/VF 6 (5.8) [0.12] 17 (18.1) [0.23]* 0.46
Worsening HF# 36 (35) [0.68] 10 (10.6) [0.12]‡ —
Rehospitalizations 64 (62) [1.43] 75 (79.8) [2.49]‡ 2.64**
Composite event rate†† 39 (38) [0.83] 62 (66) [1.89]‡ 2.09
Relative risk (95% CI) OMM/LVAD: 0.44 (0.35–0.56)‡ —
Values are n (%) for prevalence of patients within 1 year and events/patient-year [EPPY] on all data, unless
otherwise indicated. p values OMM vs. LVAD: *p < 0.05. †p < 0.01. ‡p < 0.001. §Park et al. (16). k4 patients had
50% of all gastrointestinal bleeding events. ¶Thrombus plus hemolysis. #HF symptoms resulting in unexpected
hospitalization, emergency department visit, or urgent clinic visit requiring intravenous therapy. **Slaughter
et al. (3). ††Sum of bleeding, infection, thrombus, stroke, arrhythmias, and worsening HF.
CI ¼ conﬁdence interval; DT ¼ destination therapy; EPPY ¼ events per patient-year; GI ¼ gastrointestinal;
NS ¼ not signiﬁcant; VF ¼ ventricular ﬁbrillation; VT ¼ ventricular tachycardia; other abbreviations as in Table 1.
TABLE 7 Reasons for Rehospitalizations
OMM
Rehospitalizations
(n ¼ 160)
LVAD
Rehospitalizations
(n ¼ 328)
Adverse events 97 (61) 207 (63)
Bleeding 1 (1) 79 (24)†
Worsening HF 72 (45)* 16 (5)
Elective procedure 10 (6) 22 (7)
Comorbidity management 13 (8) 16 (5)
Blood pressure/volume
management
6 (4) 16 (5)
Pain 5 (3) 12 (4)
Trauma 0 9 (3)
LVAD alarms/driveline and
controller problems
0 9 (3)
Dizziness/syncope 9 (6) 8 (2)
LVAD implantation or
exchange/
heart transplant
11 (7) 7 (2)
Anticoagulation management 0 7 (2)
Rehabilitation/hospice 4 (3) 5 (2)
Other‡ 5 (3) 10 (3)
Values are n (%) of rehospitalizations. *Most frequent OMM rehospitalization
reason was worsening HF, which included 9 delayed HMII and 1 total artiﬁcial heart
implantation. †Most frequent LVAD rehospitalization reason was bleeding. ‡In-
cludes thoracentesis, depression, fever, failure to thrive, peripherally inserted
central catheter line pulled out, dyspnea, and cellulitis.
Abbreviations as in Table 1.
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1757these 2 cohorts had different underlying disease
severity. Survival was similar in both groups in the
intention-to-treat analysis. As-treated event-free
actuarial survival over a 12-month period was signif-
icantly better with LVAD than OMM. The LVAD sur-
vival rate of 80  4% at 1 year is similar to the recently
published post-approval DT HMII study that reported
a 12-month survival of 82  5% in patients with
INTERMACS proﬁles 4 to 7 compared with 71  3% for
those with INTERMACS proﬁles 1 to 3 (7). Differences
in the primary endpoint between LVAD and OMM
were primarily due to the use of delayed LVADs in the
OMM group. Thus, the intention-to-treat analysis
suggests no mortality penalty for either early or
delayed use of LVADs in these patients, indicating
that factors beyond survival are paramount to
decision-making surrounding LVAD implantation in
this population. Patients in the OMM group avoid
complex LVAD surgery and LVAD AEs; however,
watchful waiting on OMM would not achieve the
primary beneﬁts of functional improvements and
patient-reported HRQoL with LVAD support. A full
examination to understand the beneﬁts and risks of
delayed LVAD decision is planned at the 2-year study
follow-up.
Pilot data from the medical arm of INTERMACS
(MEDAMACS), launched in January 2013, showed that
the 1-year event-free survival of death, LVAD, or
heart transplant while receiving OMM was approxi-
mately 47% (13). These observations demonstrate
that advanced, ambulatory, noninotrope-dependent
HF patients with high-grade symptoms of shortness
of breath (NYHA functional class IIIB/IV) have a poor
12-month prognosis. Considering that many medi-
cally managed HF patients with INTERMACS proﬁles
4 to 7 could potentially beneﬁt from LVAD therapy,
early referral may be warranted to carefully weigh the
projected beneﬁts versus risks for individual patients
when considering LVAD or continued OMM in this
less sick patient population with advanced HF.
Concerns persist that LVADs predispose patients to
an undue burden of AEs, including thromboembolic
and bleeding events. In the ROADMAP patient popu-
lation, bleeding, which accounted for two-thirds of all
events, was the primary driver of the high event rate
in LVAD patients and were almost 9 times the rate of
stroke-related thromboembolic events and pump
thrombus, which were comparable to ﬁndings in past
HMII trials. The rates of ischemic and hemorrhagic
stroke among LVAD patients (0.06 and 0.03 EPPY,
respectively) are similar to those among patients with
advanced HF who underwent implantation in the
HMII DT trial (0.05 and 0.03 EPPY, respectively) but
greater than the rate in patients with advanced HFenrolled in the OMM group of ROADMAP (0.01 EPPY
each for ischemic and hemorrhagic stroke). The
stroke incidence in those treated with OMM in
ROADMAP was lower than that among patients with
TABLE 8 OMM Patients Receiving Delayed LVAD
At Enrollment
(Baseline)
Before Delayed
LVAD p Value
Albumin, g/dl (n ¼ 15) 3.9 (3.7–4.1) 3.5 (3.4–3.7) <0.001
6 MWD, m (n ¼ 11) 213 (192–271) 90 (0–221) 0.004
EQ-5D VAS (n ¼ 9) 45 (38–58) 40 (28–55) 0.373
PHQ-9 (n ¼ 10) 7.5 (3.5–11.0) 10.5 (7.8–12.5) 0.289
SHFM 1-yr survival, %
(n ¼ 17)
89 (82–92) 73 (54–84) 0.012
INTERMACSproﬁle (n¼ 14) 0.031
Proﬁle 2–3 0 6 (43)
Proﬁle 4–7 14 (100) 8 (57)
NYHA functional class IV
(n ¼ 15)
4 (27) 10 (67) 0.031
Values are median (quartile1–3) or n (%).
Abbreviations as in Table 1.
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1758advanced HF who do not have device support and
have other cardiovascular conditions, such as atrial
ﬁbrillation (14,15).
In the recent past, many centers reduced the tar-
geted international normalized ratio to 2.0  0.5
(quartile 1 to quartile 3: 1.5 to 2.5) for HMII continuous-
ﬂow LVADs. The median international normalized ra-
tio in ROADMAP of 2.1 (quartile 1 to quartile 3: 1.8 to
2.5) is higher than that reported in the DT trial of
1.8 (quartile 1 to quartile 3:1.4 to 2.3) (16). In ROADMAP
patients, pump thrombosis was only 6.4% at 12FIGURE 8 Risk/Beneﬁt Analysis
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Primary End Point
Survival
NYHA Class, HRQoL, and Depression
Adverse Events
Alive at 12 mo with
Alive at 12 mo with
Δ6MWD ≥ 75m
ΔNYHA improvement ≥ 1 class
ΔEQ–5D VAS improvement > 20 points*
ΔPHQ–9 improvement ≥ 5 points†
As treated on original therapy
Intent-to-treat
Composite
Survival, changes in functional capacity, health-related quality of life (HR
favors OMM. *Includes patients with baseline VAS <68 (lowest 3 quartil
depression severity). LCL ¼ lower conﬁdence limit; OR ¼ odds ratio; UC
6, and 7.months, which was much lower than in a recent
3-center report (17) but comparable to an INTERMACS
investigation (18). In addition, LVAD patients had a
low device-related infection rate (0.14 EPPY), nearly
50% of HMII DT trial patients (16), but similar to the
low driveline infection rate (0.11 EPPY) recently re-
ported in the SSI (Silicone-Skin-Interface) Registry,
where the driveline velour was buried below the skin
(19). AEs in the OMM patients were less than one-half
that of LVAD patients, and worsening HF (the leading
cause) accounted for>80% of events. Not all AEs in the
OMM group resulted in rehospitalization, as wors-
ening HFmay be treated as an unscheduled outpatient
visit in which intensiﬁed diuretic or other pharmaco-
therapy is applied. In contrast, rehospitalizations for
the LVAD group are often due to reasons less amenable
to outpatient solutions. Many rehospitalizations may
be less likely associated with a serious adverse
outcome.
Enhancing quality of life and functional capabilities
remains a critical therapeutic goal in treating patients
with advanced HF. In our study, the use of LVAD
compared with OMM was associated with signiﬁcant
reduction in worsening HF-related readmissions, as
well as improved quality of life and functional capac-
ity. The exercise and quality of life beneﬁt with LVAD
occurred even with AEs being more frequent. Beneﬁts
included a 75-m increase in 6MWD, a 30-point
improvement in EQ-5D VAS comparable to the HMII5.0 10.0
ter
Ratio [LCL, UCL] p–value
O.R
H.R
O.R
R.R
2.4 [1.2, 4.8]  p=0.012
1.71 [1.07, 2.73]  p=0.024
1.02 [0.59, 1.77]  p=0.931
8.9 [4.5–17.8]  p<0.001
4.1 [1.9–8.9]  p<0.001
4.2 [1.7–10.2]  p<0.001
0.44 [0.35–0.56]  p<0.001
Qol), and depression favor LVAD therapy, but the adverse event rate
es). †Includes patients with baseline PHQ-9 scores >4 (mild or worse
L ¼ upper conﬁdence limit; other abbreviations as in Figures 1, 2,
CENTRAL ILLUSTRATION LVAD and Medical Management in Ambulatory HF: Treatment Algorithm to
Guide Decisions on Noninotrope-Dependent Patients With Advanced HF
Estep, J.D. et al. J Am Coll Cardiol. 2015; 66(16):1747–61.
Survival
*U.S. Food and Drug Administration (FDA) destination therapy indication includes: New York Heart Association (NYHA) functional class IIIB or IV,
left ventricular ejection fraction #25%, not listed (or planned) for heart transplantation, and on optimal medical management (OMM). †The
ROADMAP (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device [LVAD] and Medical Management) trial results with
odds, hazard, and relative risk ratios as deﬁned in Figure 8. ‡EuroQol visual analog scale improvement >20 points in patients with baseline
score <68. §Patient Health Questionnaire–9 score improvement $5 points in patients with baseline mild or worse depression severity. kSum of
bleeding, infection, thrombus, stroke, arrhythmias, and worsening heart failure. 6MWD ¼ 6-min walk distance; HF ¼ heart failure; LVAD ¼ left
ventricular assist device.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Certain ambulatory patients with advanced HF who
are not inotrope-dependent but have indications for
destination therapy treated with assist devices
(LVADs) exhibit better event-free survival, functional
capacity, and quality of life than those receiving OMM
without device support, despite a greater frequency
of AEs that are typically not fatal or disabling.
TRANSLATIONAL OUTLOOK: Randomized studies
are needed to deﬁne the beneﬁts and risks of LVADs in
patients with less severe HF.
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1760DT post-approval study (7), and the 35-point im-
provement in INTERMACS data at 1-year follow-up (8),
a reduction in depression, and improvement in sym-
ptoms corresponding to a reduction by at least 1 NYHA
functional class. The 6MWD absolute improvement at
12 months is also greater than the 45-m increase
observed in NYHA functional class IV patients treated
with cardiac resynchronization therapy (20).
Compared with the LVAD arm, OMM patients had a
higher baseline 6MWD, in addition to other baseline
parameters, consistent with a less sick patient popu-
lation, a marginal 6MWD increase, and a smaller
improvement in the EQ-5D VAS. At 12 months, 71% of
OMM patients had persistent NYHA functional class
III/IV symptoms.
The ROADMAP trial is complementary to the recent
National Institutes of Health–funded REVIVE-IT
(Randomized Evaluation of VAD Intervention before
Inotropic Therapy) trial. The intent of REVIVE-IT was
to examine LVAD versus OMM in patients with even
less advanced HF (NYHA III symptoms/INTERMACS
proﬁle 7) than ROADMAP. However, REVIVE-IT was
closed due to failed recruitment and the national
principal investigators putting the study on hold due
to concern regarding clinical equipoise (projected
beneﬁts vs. current AEs associated with LVADs). We
hope that ROADMAP provides some clarity regarding
the projected beneﬁts versus risks in a less sick pa-
tient population (INTERMACS proﬁle 4 to 7), and we
remain optimistic that randomized trials will ulti-
mately be designed and completed.
STUDY LIMITATIONS. ROADMAP was a nonrandomized,
controlled observational study of current practice and
decisions, and hence there is potential for bias. Se-
lection bias was not unexpected, as seen in the
baseline characteristics, which indicated that OMM
patients were appropriately less ill than LVAD pa-
tients. Thus, the risk/beneﬁt analyses presented may
underestimate the beneﬁt and overestimate the risk
of LVAD versus OMM. Despite these differences, more
LVAD patients still met the primary endpoint. The
withdrawn percentage was 3 times greater in the
OMM (9%) versus the LVAD (3%) group and may in-
ﬂuence the results. The LVAD used in this study was
HMII, and the risk/beneﬁt analyses are not general-
izable to other mechanical circulatory support
devices. There is well-known bias regarding patient-
reported questionnaires and outcomes, including
HRQoL and depression. AEs were reported by treating
physicians and not adjudicated by a clinical events
committee; we do not believe that this affected the
study primary endpoint. In addition, important de-
terminants of the appropriateness of LVADs,including frailty, nonadherence to therapy, and social
support, were not collected but may have important
implications that could skew the results. The study
was also performed in a selected patient population,
and applicability to the broader population of
noninotropic-dependent patients with HF, including
those with less hemodynamic and functional
compromise than ROADMAP patients, would be
speculative. Many ﬁndings and endpoints of this
observational study should be considered hypothesis
generating and need to be conﬁrmed with other
studies, including randomized controlled trials where
appropriate.
CONCLUSIONS
To the best of our knowledge, this study is the ﬁrst
prospective clinical evaluation of patients with
advanced ambulatory HF demonstrating a favorable
outcome comparing treatment with LVADs versus
OMM. Survival with improved functional status was
better with LVADs in this less sick HF population.
There was low LVAD operative mortality. HRQoL and
depression improvedmore with LVADs, even with AEs
being more frequent. ROADMAP provides new and
very important risk/beneﬁt information to guide pa-
tient and physician decision-making regarding LVAD
therapy in an ambulatory, advanced HF population
(Central Illustration). The results support the use of the
HMII LVAD under existing approved indications in
functionally limited noninotrope-dependent HF pa-
tients with poor quality of life.
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